Equities Analysts Offer Predictions for PVLA FY2026 Earnings

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Stock analysts at Lifesci Capital cut their FY2026 earnings per share estimates for Palvella Therapeutics in a research report issued to clients and investors on Wednesday, April 1st. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings per share of ($6.11) for the year, down from their previous estimate of ($4.49). The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.13).

Several other equities analysts also recently commented on the stock. Stifel Nicolaus set a $250.00 target price on shares of Palvella Therapeutics in a report on Tuesday, February 24th. TD Cowen reaffirmed a “buy” rating on shares of Palvella Therapeutics in a research note on Monday, February 2nd. BTIG Research lifted their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Raymond James Financial reiterated a “strong-buy” rating and issued a $193.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. Finally, Chardan Capital raised their price objective on Palvella Therapeutics from $210.00 to $240.00 and gave the company a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $198.07.

Palvella Therapeutics Price Performance

Shares of PVLA opened at $123.46 on Friday. Palvella Therapeutics has a 1 year low of $18.23 and a 1 year high of $151.18. The company has a 50 day simple moving average of $107.19 and a two-hundred day simple moving average of $92.55. The firm has a market cap of $1.77 billion, a P/E ratio of -33.28 and a beta of -0.21.

Institutional Trading of Palvella Therapeutics

Several hedge funds have recently made changes to their positions in PVLA. First Light Asset Management LLC purchased a new position in Palvella Therapeutics in the third quarter worth about $33,949,000. Summit Partners Public Asset Management LLC raised its position in Palvella Therapeutics by 1,016.0% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock valued at $40,761,000 after purchasing an additional 354,525 shares during the period. Federated Hermes Inc. purchased a new stake in Palvella Therapeutics during the third quarter valued at approximately $21,255,000. Vanguard Group Inc. lifted its stake in shares of Palvella Therapeutics by 202.0% in the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after purchasing an additional 330,847 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Palvella Therapeutics by 206.3% in the 4th quarter. State Street Corp now owns 420,462 shares of the company’s stock valued at $44,010,000 after purchasing an additional 283,211 shares during the last quarter. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Palvella Therapeutics

In other Palvella Therapeutics news, Director Elaine J. Heron bought 2,400 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was purchased at an average cost of $125.00 per share, with a total value of $300,000.00. Following the completion of the acquisition, the director owned 47,812 shares in the company, valued at $5,976,500. This trade represents a 5.28% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. The disclosure for this sale is available in the SEC filing. 20.50% of the stock is currently owned by insiders.

Palvella Therapeutics News Summary

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: HC Wainwright sharply raised long‑term EPS forecasts and reiterated a Buy rating with a $270 target — FY2028 to $2.08 (from -$1.84), FY2029 to $9.00 (from $2.19) and FY2030 to $22.29 (from $11.56). These large upward revisions signal the firm expects material value creation farther out, which tends to support higher share valuations. MarketBeat HC Wainwright Coverage
• Positive Sentiment: Chardan Capital coverage noted an expectation the stock price will rise, adding an independent bullish voice that can amplify buying interest. Article Title
• Neutral Sentiment: HC Wainwright also published detailed 2026 quarterly forecasts (Q1 2026: -$0.89; Q2: -$1.02; Q3: -$1.19; Q4: -$1.30). These short‑term loss projections provide a clearer operating path but do not change the firm’s long‑term bullish stance. MarketBeat Q‑trends
• Negative Sentiment: HC Wainwright trimmed near‑term estimates — FY2026 EPS down to ($4.41) from ($3.28) and FY2027 to ($3.76) from ($3.43) — indicating a worse short‑term profitability outlook that can pressure sentiment for investors focused on near‑term results. MarketBeat Near‑term Cuts
• Negative Sentiment: Lifesci Capital lowered its FY2026 estimate to ($6.11) from ($4.49), a notably deeper loss projection that reinforces near‑term downside risk and highlights analyst disagreement on the timing of recovery. MarketBeat Lifesci Note

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.